Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Forest Laboratories, Inc. (NY: FRX)
41.57 USD  UNCHANGED
Official Closing Price  /  Updated: 6:40 PM EDT, Jun 18, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Forest Laboratories, Inc.
 
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Research Abstracts, Phase 2 Results, and Market Availability of Formulations and Treatments- Research Report on Teva, Forest, Pharmacyclics, Cubist, and Dr. Reddy's
Today 8:00 EDT
Editor Note: For more information about this release, please scroll to bottom Read More
from PR Newswire
Forest Announces U.S. Availability of New Once-Daily NAMENDA XR
June 13, 2013
from Business Wire News Releases
Forest Laboratories Appoints New Independent Director
June 11, 2013
from Business Wire News Releases
Forest Laboratories Provides Update on Succession Planning
May 23, 2013
from Business Wire News Releases
Forest to Present Aclidinium Bromide and Roflumilast Clinical Data at the American Thoracic Society (ATS) International Conference
May 17, 2013
from Business Wire News Releases
Forest Laboratories, Inc. to Present Data from Cariprazine and Levomilnacipran Phase 3 Trials at American Psychiatric Association Annual Meeting
May 16, 2013
from Business Wire News Releases
Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2013
May 14, 2013
from Business Wire News Releases
Trevena Inc. and Forest Laboratories Announce a Collaborative Agreement for Development of TRV027 for the Treatment of Acute Heart Failure
May 09, 2013
from Business Wire News Releases
Trevena, Inc. and Forest Laboratories Announce a Collaborative Agreement For Development of TRV027 for the Treatment of Acute Heart Failure
May 09, 2013
Forest Laboratories leads Trevena's $60 Million Series C Funding Round; All existing investors to also participate Read More
from PR Newswire
Forest Laboratories and Almirall Announce Positive Results for the Second Phase III Study for Aclidinium and Formoterol combination in COPD
May 01, 2013
from Business Wire News Releases
Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2013 Earnings Per Share of $0.17 Including $0.08 Per Share of Acquisition Amortization
April 23, 2013
from Business Wire News Releases
Almirall and Forest Laboratories Announce Positive Phase III Study Results for Aclidinium and Formoterol Combination in COPD
April 16, 2013
from Business Wire News Releases
Mylan, Akorn, Astex Pharma, and Forest Laboratories Under StockCall's Microscope
April 08, 2013
from PR Newswire
Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2013 Fourth Quarter Earnings
April 02, 2013
from Business Wire News Releases
NIRI Appoints Charles Triano to Board of Directors
March 20, 2013
from Business Wire News Releases
Before the Bell Scans of Mylan, Forest Laboratories, Avanir Pharma, Akorn, and Medicines Co.
March 08, 2013
from PR Newswire
Amarin and Forest Laboratories Under Review: Drug Makers Face Growing Generic Competition
February 15, 2013
from PR Newswire
From Perspectives to Struggles, Alzheimer's Family Caregivers Find Strength in Sharing
February 05, 2013
-- Caregiver Action Network Introduces Online Video Series Featuring Powerful Insights from Caregivers Across the Country -- Read More
from PR Newswire
Forest Laboratories, Inc. Announces Health Canada Approval of BYSTOLIC for the Treatment of Hypertension
January 17, 2013
from Business Wire News Releases
Forest Laboratories, Inc. Reports Fiscal Year 2013 Third Quarter Earnings
January 15, 2013
from Business Wire News Releases
MAS, JNS, GGC and FRX Freshly Hit a New 52-Week High
January 14, 2013
from Marketwired News Releases
Forest Laboratories, Inc. Announces Additional Settlement Agreement in BYSTOLIC® Patent Litigation
January 03, 2013
from Business Wire News Releases
Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2013 Third Quarter Earnings
January 02, 2013
from Business Wire News Releases
Ironwood and Forest Announce U.S. Availability of LINZESS™ (Linaclotide)
December 17, 2012
from Business Wire News Releases
Forest Laboratories and Almirall announce commercial availability of Tudorza™ Pressair™ in US pharmacies
December 11, 2012
from Business Wire News Releases
Forest Laboratories, Inc. to Present Cariprazine Results from a Phase 3 Trial and Two Pharmacology Studies at the American College of Neuropsychopharmacology (ACNP) Annual Meeting
December 03, 2012
from Business Wire News Releases
Forest Laboratories, Inc. Announces Additional Settlement Agreements in BYSTOLIC® Patent Litigation
November 28, 2012
from Business Wire News Releases
Forest Laboratories Submits New Drug Application for Cariprazine for the Treatment of Both Schizophrenia and Manic or Mixed Episodes Associated with Bipolar I Disorder
November 28, 2012
from Business Wire News Releases
Forest Laboratories and Adamas Pharmaceuticals Enter into Licensing Agreement for the Development and Commercialization of a Fixed Dosed Combination of Namenda XR® and Donepezil for Alzheimer’s Diseas
November 14, 2012
from Business Wire News Releases
/C O R R E C T I O N -- Sanford Heisler, LLP/
November 05, 2012
from PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here

WHAT'S POPULAR IN THE VILLE

1
The QE Carry Trade Is Imploding Right Under Everyone's Noses
Vince Foster
2
Immunotherapy: Four Companies on the Verge of Cancer-Treatment Breakthroughs
TM Meyer
3
Why Apple Inc. Can't Be Forgiven for iOS 7
Mike Schuster
4
In Insider Trading, Phillip Frost Increases Stake in Opko Health Inc. and Larry Page Sells Shares of Google Inc
Jonathan Moreland
5
What Now, Mr. Bernanke? Traders Position Into the FOMC Rate Decision
Todd Harrison